Sanofi and Regeneron wanted to make a deal: They would drop the cost of their PCSK9 inhibitor Praluent (alirocumab) for improved access. Express Scripts took them up on the offer and gave Praluent preferred access over Amgen’s Repatha on its national formulary. It also removed restrictions that impaired market access for PCSK9 inhibitors. In return, Express Scripts gets a higher rebate on the wholesale acquisition cost of the drug. Is it the start of a trend or just a one-off? Find out. Learn whether this deal will affect the exceptionally high rejection rate for PCSK9 drugs. Gain insight into whether PCSK9 manufacturers miscalculated when they initially set prices.